Literature DB >> 12468521

Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers.

Li Lu1, Linda Samuelsson, Mats Bergström, Kengo Sato, Karl-Johan Fasth, Bengt Långström.   

Abstract

UNLABELLED: We analyzed and compared 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-[methyl-(11)C]thymine ((11)C-FMAU), 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-[(76)Br]bromouracil ((76)Br-BFU) with respect to tissue uptake, DNA incorporation, and excretion modulation in rats. The goal of the investigation was to evaluate the efficiency of the 3 nucleoside tracers as potential tracers for measuring proliferation.
METHODS: Sprague-Dawley rats were divided into 3 groups and administered 5 MBq (11)C-FMAU, 1 MBq (18)F-FLT, or 2 MBq (76)Br-BFU. For each tracer, a subgroup was also administered 6 mg/kg cimetidine. The rats in the (11)C-FMAU group were killed at 5, 20, 40, 60, and 80 min after injection; the rats in the (18)F-FLT group were killed at 80 min and 2 and 4 h; and the rats in the (76)Br-BFU group were killed at 5, 20, 40, and 80 min and 2, 4, 6, and 24 h. Samples of blood, liver, kidney, spleen, and intestine were taken, and the radioactivity was measured. DNA separation was made in the samples of spleen, and the radioactivity in the DNA fraction was measured.
RESULTS: Maximal uptake of radioactivity was seen in the spleen and intestine, organs with active DNA synthesis. The highest relative radioactivity uptake was at 60 min in the (11)C-FMAU groups and at 4 h in the (18)F-FLT group. In the (76)Br-BFU group, the uptake increased gradually during the observation period, and uptake of radioactivity increased markedly in rats receiving cimetidine. Cimetidine did not affect radioactivity uptake in the (11)C-FMAU or (18)F-FLT groups. The fraction of radioactivity in DNA was 78% in spleen at 60 min in the (11)C-FMAU group, 80% at 60 min and 97% at 4 h in the (76)Br-BFU group. The DNA-incorporation was only 2% in the (18)F-FLT group.
CONCLUSION: (76)Br-BFU predominantly incorporates into DNA and has great potential as a PET tracer for the assessment of proliferation in vivo. (11)C-FMAU also may have potential as a proliferation marker, but the observation time is limited. (18)F-FLT does not incorporate into DNA and is therefore not a direct marker of proliferation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468521

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.

Authors:  David A Plotnik; Lindsay E Emerick; Kenneth A Krohn; Jashvant D Unadkat; Jeffrey L Schwartz
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

2.  The role of 18F-FLT in cancer imaging: does it really reflect proliferation?

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

3.  Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.

Authors:  Betty S Pio; Cecilia K Park; Richard Pietras; Wei-Ann Hsueh; Nagichettiar Satyamurthy; Mark D Pegram; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

4.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

5.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

6.  A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.

Authors:  Anthony F Shields; David A Briston; Samatha Chandupatla; Kirk A Douglas; Jawana Lawhorn-Crews; Jerry M Collins; Thomas J Mangner; Lance K Heilbrun; Otto Muzik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-01       Impact factor: 9.236

7.  The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells.

Authors:  David A Plotnik; Lena J McLaughlin; Jenny Chan; Joshua N Redmayne-Titley; Jeffrey L Schwartz
Journal:  Nucl Med Biol       Date:  2011-06-22       Impact factor: 2.408

8.  Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture.

Authors:  Keon Wook Kang; Jung-Joon Min; Xiaoyuan Chen; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

9.  [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Authors:  Nicolas Graf; Ken Herrmann; Barbara Numberger; Daniela Zwisler; Michaela Aichler; Annette Feuchtinger; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Peschel; Markus Schwaiger; Ulrich Keller; Tobias Dechow; Andreas K Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

10.  Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.

Authors:  Nicolas Graf; Ken Herrmann; Jürgen den Hollander; Falko Fend; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Meyer zum Büschenfelde; Christian Peschel; Markus Schwaiger; Tobias Dechow; Andreas K Buck
Journal:  Mol Imaging Biol       Date:  2008-08-14       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.